Emelia J. Benjamin, MD, ScM
Dr. Benjamin received her undergraduate degree at Harvard, her MD at Case Western Reserve University, and her Master’s in Epidemiology at Harvard School of Public Health. She is a Professor of Medicine at Boston University and is a clinical cardiologist at Boston Medical Center. At the Framingham Heart Study, she serves as Director of the Echocardiography and Vascular Function Laboratories and a Member of the Executive Committee and Genetics Steering Committee. She has done research at the Framingham Study over the past 17 years on the genetics, epidemiology, and prognosis of the following: atrial fibrillation, cardiac risk factors for stroke, echocardiography, valvular pathology, vascular function and the relation of systemic inflammation to cardiovascular disease. She is Principal Investigator on 2 NHLBI RO1 grants investigating the association of inflammation (R01 HL76784) and of vascular function (1RO1 HL70100, arterial tonometry to assess vascular stiffness and brachial reactivity to assess endothelial function) to subclinical and clinical cardiovascular disease. She also serves as Principal Investigator of the Framingham Component of the CardioGenomics Program in Genomics Applications, which is investigating the genetics of cardiac structure and function in collaboration with the Broad Institute and Harvard Medical School. Dr. Benjamin has volunteered for the American Heart Association for the past twelve years; serving on a variety of local and national Committees. Currently she serves as a member of the national American Heart Association’s Interdisciplinary Working Group Steering Committee Functional Genomics & Translational Biology and is Co-Chair of the Conference “Discovering the Full Spectrum of Cardiovascular Disease – Addressing Ethnic Disparities”. She has derived tremendous professional growth and personal pleasure in successfully mentoring residents, fellows and junior faculty in conducting and publishing studies in the field of cardiovascular disease epidemiology.
Richard A Cohen, MD
Dr. Cohen is the Jay and Louise Coffman Professor of Vascular Medicine and the Director of the Vascular Biology Unit. Dr. Cohen is also co-principal investigator of the BU NIH Cardiovascular Proteomics Center. Dr. Cohen received his MD from Johns Hopkins School of Medicine, and trained in Internal Medicine at Boston Medical Center. His clinical expertise is the diagnosis and management of arterial and venous peripheral vascular disease including intermittent claudication, venous thrombosis and phlebitis, and vasospastic diseases. Dr. Cohen has been continuously funded for over 20 years by the National Institutes of Health to study physiological and molecular vascular biology. He is now funded by three R01 grants and participates as project leader in two additional program grants. The research programs of the Vascular Biology Unit are directed towards an integrative molecular understanding of abnormal vascular endothelial and smooth muscle cell function in diseased blood vessels and its contribution to abnormal vascular reactivity and atherogenesis. Research projects focus on the mechanisms by which vascular risk factors associated with diabetes mellitus, hypercholesterolemia, and hypertension lead to abnormal production of vasoactive factors from the endothelium and also how they alter the responses of cells within the vascular wall. These factors include nitric oxide, prostanoids, oxygen-derived free radicals, cytokines, and growth factors. Experimental approaches employ cell physiology of cultured endothelial and smooth muscle cells with measurements of intracellular calcium and oxygen-derived free radicals, coupled with studies of molecular signaling. The influence of altered production of endothelial factors and signaling cascades on inflammatory responses and cell adhesion is studied as it applies to the development of atherosclerotic lesions, particularly in diabetes. Post-translational modification by tyrosine nitration and thiol oxidation of proteins studied by immuno/affinity labeling and mass spectrometry has been shown to alter the function of endothelial cell nitric oxide synthase, sarcoplasmic reticulum ATPase, endothelial nitric oxide synthase, manganese superoxide dismutase, and prostacyclin synthase. Proteomic approaches are being used to screen proteins for oxidant modifications that occur as physiological mechanisms or are a consequence of excess reactive nitrogen species. These numerous investigations into mechanisms of vascular dysfunction may serves as the foundation for translational or mechanistic research endeavors for our fellows.
Adrienne Cupples, PhD
Dr. Cupples has expertise in study design and statistical methods, as well as experience in training clinical researchers. Dr. Cupples is Professor and Chair of Biostatistics and Professor of Epidemiology at Boston University School of Public Health. An experienced biostatistician, she is a popular teacher in the School, teaching introductory biostatistics, statistical methods in epidemiology and more recently analytic approaches to correlated data. She is also an active collaborator in the Framingham Heart Study, serving as a senior statistician in genetic studies of cardiovascular disease and associated risk factors. She is Co-Director of the Framingham Study Genetics Steering Committee, and is a member of the Framingham Heart Study Executive Committee. Dr. Cupples is also an active researcher in Alzheimer’s disease, particularly the MIRAGE project (Multi-Institutional Research in Alzheimer’s Genetic Epidemiology) and in the REVEAL project that is evaluating the safety and effects of disclosing genetic information to first-degree relatives of AD subjects. Her research focuses on biostatistical methods for epidemiological studies, survival analysis and genetic epidemiology. She currently interacts frequently with MD clinical investigators at BUMC as a statistical consultant and mentors several trainees in the doctoral program in Biostatistics. Dr. Cupples has taken a lead in the redesign of the introductory course taught in the summer to incoming CREST fellows and frequently teaches this course. The inclusion of Dr. Cupples on the advisory committee will provide assurances that appropriate attention is paid to the design and analysis of the proposed research projects of our fellows.
Laura Dember, MD
Dr. Dember is an Associate Professor of Medicine at Boston University School of Medicine, Director of the Dialysis Program at Boston Medical Center, and a clinical nephrologist. Dr. Dember is an established investigator in Vascular Medicine with a specific research interest in vascular access for maintenance hemodialysis. She is a Principal Investigator for the NIH-sponsored Dialysis Access Consortium, a multi-center group established to design and conduct clinical trials evaluating interventions to improve hemodialysis vascular access outcomes. The Dialysis Access Consortium is currently conducting two parallel, large multi-center trials evaluating interventions for autogenous arteriovenous fistulae and synthetic arteriovenous grafts. Dr. Dember is the lead investigator for one of these trials, and is the lead investigator for ancillary studies addressing the mechanisms underlying vascular access failure. In addition to her role in the Dialysis Access Consortium, Dr. Dember has conducted both single center and multi-center investigator-initiated studies in the field of vascular access, and is a member of a collaborative group studying cardiovascular disease associated with chronic kidney disease and end-stage renal disease. She is a member of the Steering Committee of the NIDDK Kidney Disease Clinical Studies Initiative and has served on ad hoc review groups for NIDDK-initiated RFAs. Dr. Dember has served as a mentor for research fellows in the Boston University Nephrology Fellowship Training Program as well as for undergraduate students at Harvard College and Boston University. She has established collaborative relationships with members of the Cardiology Section and Interventional Radiology Divisions at Boston University. Dr. Dember’s clinical research resources and access to large chronic kidney disease and end-stage renal disease patient populations together with the expertise in vascular biology at Boston University provide important opportunities for research training in the areas of hemodialysis vascular access failure and vascular disease associated with chronic kidney disease.
Dr. Eberhardt is an Associate Professor of Medicine at Boston University School of Medicine and Director of Medical Vascular Services at Boston Medical Center. He is a fellow of the American College of Cardiology, Council on Clinical Cardiology of the American Heart Association, and the Society for Vascular Medicine and Biology. He is board certified in internal medicine, cardiovascular diseases, and vascular medicine. After completing fellowship training in 1999, he joined the faculty of the section of Peripheral Vascular Medicine and since Cardiovascular Medicine at Boston Medical Center. His clinical expertise is in the evaluation and management of vascular disorders, including arterial, venous, lymphatic, thrombotic, and vasospastic disorders. He emphasizes the systemic nature of atherosclerosis with efforts to treat modifiable risk factors and prevent cardiovascular complications – serving as co-director of the Lipid Clinic at Boston Medical Center. Dr. Eberhardt has expertise in non-invasive vascular imaging, and is a registered vascular technologist, registered physician in vascular interpretation, and co-director of the vascular laboratories at Boston Medical Center and Quincy Medical Center. His expertise in vascular laboratory testing and quality assurance issues is demonstrated by his being elected on the Board of Directors for the Intersocietal Commission for Accreditation of Vascular Laboratories. He has served as an item writer for the board exam in vascular medicine and committee chair for the Emerging Leadership Committee for the Society for Vascular Medicine and Biology.
Dr. Eberhardt’s research interests include studying the mechanisms and contribution of vascular and endothelial dysfunction and impairment in nitric oxide bioactivity to the pathophysiology of several disorders including sickle cell disease, coronary artery disease and peripheral arterial disease. He has studied the effects of hyperhomocysteinemia on endothelial function and oxidant burden in a murine model of cystathionine beta-synthase deficiency. He conducted translational investigations on the effects of sickle cell disease on vascular function as the Research Scholar for the Boston Comprehensive Sickle Cell Center. He has investigated the effect of creatine supplementation on the response to L-arginine in coronary heart disease. His more recent focus has been in peripheral arterial disease, serving as an investigator on an NIH-funded grant entitled “Clinical Utility of Endothelial Function in PAD”.
Harrison Farber, MD
Dr. Farber is Professor of Medicine at Boston University School of Medicine and Director of the Pulmonary Hypertension Center at Boston Medical Center. He is an established investigator in Vascular Medicine with a specific research interest in endothelial responses to inherent stresses, particularly hypoxia, and the phenotypic changes of pulmonary vascular endothelial cells that lead to development of pulmonary hypertension. He is a Principal Investigator on several NIH-funded projects including development of mouse models of pulmonary vascular disease in sickle cell anemia, proteomic changes of endothelial cells in sickle cell vascular disease and the response of endothelial cell to hypoxia and reactive oxygen species via a subset of phospholipids, the plasmalogens. In addition, Dr. Farber is a recognized leader in treatment of pulmonary hypertension and has been an investigator in several clinical trials of newer medications for the treatment of pulmonary arterial hypertension. He has served on numerous NIH and AHA study sections and is on the Leadership Council of the CPCC section of the AHA. Dr. Farber is the principal investigator for the Pulmonary Circulation research group in the Pulmonary Center and has served as a mentor for research fellows in the Boston University Pulmonary and Critical Care Fellowship Training Program as well as for undergraduate students at Boston University. He has established collaborative research relationships with members of the Cardiology, Rheumatology, Hematology and Biophysics Sections at Boston University. Dr. Farber’s clinical and bench research resources and access to an exceptionally large population of patients with pulmonary hypertension together with the expertise in vascular biology at Boston University provide numerous opportunities for research training in the area of cardiopulmonary vascular disease.
David T. Felson, MD, MPH
Dr. Felson is well credentialed to serve on advisory committee with expertise in training clinicians for research careers. Dr. Felson, a rheumatologist, is a Professor of Medicine and Public Health (Epidemiology) at Boston University School of Medicine and Chair of the Clinical Epidemiology Research and Training Unit at Boston University Medical Center. Dr. Felson’s main areas of research have been in musculoskeletal epidemiology and clinical trial methodology in musculoskeletal diseases. He is PI of the Multidisciplinary Clinical Research Center Grant, a NIH P60, which funds a multidisciplinary team of clinical researchers to carry out a diverse group of clinical studies in arthritis and musculoskeletal diseases. He is also PI of the Framingham Osteoarthritis Study and Multicenter Osteoarthritis Study, both NIH grants. His work has focused mostly on osteoarthritis, including identifying the causal link between obesity and osteoarthritis. He also founded the Framingham Osteoporosis Study and has spearheaded standardization of trial methods in rheumatology. He was elected to ASCI in 1993 and to AAP in 2003.
Dr. Felson’s interest in training clinical investigators is readily apparent. He has mentored numerous trainees to pursue clinical research careers and obtain faculty positions and independent research funding. Beyond mentoring trainees, he has developed and is the Director of the CREST (Clinical Research Training) Program, a NIH K30. This program was developed to assure that trainees who wish to pursue academic clinical investigative careers have the knowledge and skills required. The trainees in the Research Career Development Program in Vascular Medicine will participate in the CREST program as the major didactic element of their research training.
Jane E. Freedman, MD
Dr. Freedman is an Associate Professor of Medicine, Pharmacology, and Experimental Therapeutics at Boston University School of Medicine. She received her BA from Yale University, MD from Tufts University, and completed her Medicine and Cardiology training at Massachusetts General Hospital and Brigham and Women’s Hospital, respectively. Dr. Freedman currently serves on study sections for the NHLBI and the AHA as well as multiple committees for the National AHA. Her major research initiatives over the past 20 years involve the study of the regulation of molecular pathways contributing to thrombosis, vascular disease, and how these factors contribute to acute coronary syndromes. The main topics include; 1) Platelet signaling pathways; 2) Molecular regulation of platelet nitric oxide and reactive oxygen species; 3) Relationship of thrombosis to atherosclerosis and coronary disease; 4) Inflammation and thrombosis. Dr. Freedman is currently an Established Investigator from the National American Heart Association and is the PI on the NIH funded awards: Thrombosis, Aging, and eNOS Polymorphisms from the NHLBI/AG (RO1AG08226-11) and Platelet-Derived Nitric Oxide and Hemostasis from the NHLBI (RO1HL62267-4). These projects include studies examining the specific pathways regulating receptor expression and their effect on thrombosis and disaggregation. The basic studies have been extended into the clinical setting and have included the role of pharmacological therapies on various molecular pathways relevant to hemostasis. Recent projects have examined genetic expression and genetic variants in subjects with unstable coronary syndromes. Using these findings, the role of innate immunity in the atherothrombotic process is being investigated both in molecular and animal studies. Dr. Freedman has a tract record for mentoring investigators at every level of training including clinical cardiovascular trainees. Dr. Freedman’s topics of investigation, technical expertise, and mentoring ability, all provide a fertile ground for development of vascular research for fellows.
Dr. Gokce is an Associate Professor of Medicine at Boston University School of Medicine and Associate Director of Echocardiography at Boston Medical Center. He is a fellow of the American College of Cardiology and American Society of Echocardiography. He is board certified in Internal Medicine, Cardiovascular Diseases, and Adult Echocardiography. Dr. Gokce is an Honors graduate of Tufts University School of Medicine, and completed his Internal Medicine training at Beth Israel Hospital, Boston. Following fellowship training at Boston Medical Center in 1998, he joined the cardiovascular faculty at Boston Medical Center and provides expertise in general cardiology, cardiovascular imaging, and echocardiography. He is the recipient of an excellence in clinical teaching award in 2006 in the cardiovascular division at BMC.
Dr. Gokce’s research interests currently focus on elucidating mechanisms of vascular dysfunction in several disorders including peripheral arterial disease, coronary artery disease, metabolic syndrome, and obesity. He has conducted several key translational studies demonstrating the prognostic role of endothelial dysfunction for future cardiovascular events. He is currently the Principal Investigator in two NIH-sponsored R01 grants entitled “Obesity, Adipocytokines, and Endothelial Dysfunction” and “Inflammation and Vascular Dysfunction in Obesity”. These studies seek to characterize the relationship between obesity and vascular endothelial dysfunction, and determine whether weight alteration and risk factor modification improve arterial health, markers of inflammation and oxidative stress, and adipocyte metabolism. The projects also examine the relationship between inflammatory activity in adipose stores and systemic arterial endothelial dysfunction. Dr. Gokce is also a co-investigator on a separate NIH-funded grant entitled “The Clinical Utility of Endothelial Function in PAD” and has served on several AHA and NIH-sponsored grant review committees.
Dr. Kalish is the Laszlo N. Tauber Assistant Professor of Surgery at Boston University School of Medicine, and Director of Endovascular Surgery at Boston Medical Center. He is a graduate of Harvard University in Massachusetts and New York University School of Medicine in New York. He has completed general surgery training at Boston Medical Center and a fellowship in vascular surgery at Beth Israel Deaconess Medical Center in Boston. He is board certified in General Surgery and Vascular Surgery. He is a member of the American College of Surgeons and the Society for Vascular Surgery. His clinical expertise includes the following: endovascular aortic surgery, peripheral interventions, diabetic vascular disease and dialysis access.
Dr. Kalish joined the General Surgery Division at Boston University in 2009. He has since participated in optimizing the Endovascular Program working closely with the divisions of Interventional Cardiology, and Interventional Radiology. Dr. Kalish is currently serving as the primary investigator at BMC for industry-sponsored clinical trials involving venous ulcers.
Carlos Kase, MD
Dr. Kase is a Professor of Neurology at Boston University School of Medicine and Director of the Stroke Service at Boston Medical Center. Dr. Kase completed his medical school education at the Catholic University of Chile, training in Neuropathology, Neurology and a Stroke Fellowship at Massachusetts General Hospital. He participated in forming the Neurology Department at the University of South Alabama in Mobile, Alabama prior to joining the Department of Neurology at Boston University School of Medicine in 1984. Dr. Kase is an Honorary Member of the Spanish Society of Neurology, and a Corresponding Member, Chilean Society of Neurology, Neurosurgery, and Psychiatry. He has received other honors including numerous teaching awards, the C. Miller Fisher Award for Excellence in Stroke from the American Stroke Association, and was awarded a Doctor Honoris Causa degree from the University of Santiago de Compostela, Spain in 2002.
Dr Kase’s professional interests have been in the area of cerebrovascular diseases, performing clinical studies and clinico-pathologic correlations in intracerebral hemorrhage and cerebral infarction. Research activities have included participation in multicenter studies such as the Stroke Data Bank (NINCDS), epidemiologic studies such as the Framingham Study, and therapeutic trials that have included: Canadian-American aspirin trial in TIAs, hypervolemic hemodilution in acute ischemic stroke (NINCDS), EC/IC bypass study (NINCDS), the Ticlopidine-Aspirin Stroke Study (TASS), Nimodipine in acute ischemic stroke, thrombolysis with tPA in acute ischemic stroke, heparinoids in acute cerebral infarction (NINDS), NMDA receptor antagonists in acute ischemic stroke, North American Symptomatic Carotid Endarterectomy Trial (NASCET) (NINDS), Warfarin-Aspirin Recurrent Stroke Study (WARSS) (NINDS), the Warfarin-Aspirin in Symptomatic Intracranial Disease (WASID) trial, and the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. Dr. Kase provides clinical expertise in the treatment and prevention of stroke.
John F. Keaney, MD
Dr. Keaney recently moved to the University of Massachusetts Medical Center and serves as Chief of the Section of Cardiovascular Medicine. Prior to his departure, Dr. Keaney was actively involved in clinical and research training at Boston University Medical Center. He served as the Program Director for the Cardiovascular Fellowship Training Program at Boston Medical Center from 2001-2005 and also led the Boston University Medical Center Basic Science Training Grant in Cardiovascular Disease. He has served as mentor for some 22 trainees in cardiovascular research. Thus, he brings important perspectives to all aspects of clinical and research fellowship training and serves as a key external advisor to the program.
Dr. Keaney’s research interests center on the redox environment and biology of endothelial cells and their contribution to maintaining normal vascular function. He is the author of some 150 original research articles, review articles, and book chapters and has edited a book entitled “Oxidative Stress and Vascular Disease.” His research accomplishments include receiving a Clinical Investigator Development Award from the NIH and an Established Investigator Award from the American Heart Association as well as over 20 invited lectureships, both nationally and internationally over the past two years. Dr. Keaney is an Executive Committee member of the Society for Free Radical Biology and Medicine and serves on the editorial board of Free Radical Biology and Medicine. He is an Associate Editor of Circulation as well as the Editor for its Basic Science for Clinicians review series. He has been Chair of the American Heart Association Cardio-Renal Review Panel and is currently a member of the Vascular Cell and Molecular Biology review panel for the National Institutes of Health. His research efforts have been funded through grants from both the NIH and AHA.
Peter A. Merkel, M.D, M.P.H.
Dr. Merkel is an Associate Professor of Medicine who holds a joint appointment in the Section of Rheumatology and the Clinical Epidemiology Unit of Boston University School of Medicine. Dr. Merkel serves a variety of roles at the Medical Center that directly enhances his qualifications as a mentor for the proposed training grant, including the Director of the Boston University Vasculitis Center, the Director and Principal Investigator of the NIH Vasculitis Clinical Research Consortium, and Associate Program Director for the Boston University General Clinical Research Center. Dr. Merkel has an excellent record for mentoring trainees in clinical investigation at every level of medical training including individuals who now are independent and well-funded investigators. Dr. Merkel is the recipient of a NIH Mid-Career Clinical Investigator Award (K24) from the National Institute of Arthritis Musculoskeletal and Skin Diseases and is a faculty member within the Boston University K30 Clinical Research Training Program (CREST Program). As Principal Investigator of the Vasculitis Clinical Research Consortium, Dr. Merkel directs the Fellowship Program that sponsors trainees to develop clinical research skills in vasculitis at Boston University and other VCRC member institutions.
Resources available to Dr. Merkel are substantial and will help support the overall goals of the proposed training program. The Boston University Vasculitis Center is the largest program for the care and research of patients with vasculitis in the Northeast. The Vascular Medicine fellows would have access to a substantial number of patients and resources, both to develop clinical expertise as well for enrollment into clinical research projects. The Boston University Vasculitis Center is extremely well-funded from the NIH and strongly supported by the University and the Medical Center. Additionally, Dr. Merkel is Associate Program Director for the GCRC with a mandate to mentor new clinical investigators; thus, the resources of the GCRC would be readily available for Vascular Medicine fellows. Dr. Merkel is also a faculty member in the Clinical Epidemiology Unit, which includes some of the leading epidemiologists, biostatisticians and clinical investigators on campus. The ability to interact with this group would be another added advantage to Vascular Medicine fellows. Dr. Merkel’s research is well-suited for inclusion of Vascular Medicine fellows that would be supported by the current proposal. He directs a series of projects in vasculitis that range from investigator-initiated, NIH-supported clinical therapeutic trials in small and large vessel vasculitides to investigator-initiated outcome measure development projects and, and clinical epidemiology studies. His studies of the large vessel vasculitides, including Takayasu’s arteritis and giant cell arteritis, are particularly relevant to Vascular Medicine fellows. He has developed a strong working relationship with both basic scientists at the Medical Center as well as vascular medicine clinicians, radiologists, cardiologists, nephrologists, and other specialists directly relevant to the study of the inflammatory vasculitides. Thus, Dr. Merkel’s commitment to mentoring clinical investigators and his ongoing research infrastructure and projects in Vascular Medicine make him an excellent potential mentor for Vascular Medicine fellows.
Alexander Norbash, MD
Dr. Norbash is Professor and Chairman of the Department of Radiology at Boston University Medical Center. He was most the prior director of Diagnostic and Interventional Neuroradiology at Brigham and Women’s Hospital, and an Associate Professor of Radiology at Harvard Medical School. He is the founding director of the Interventional Neuroradiology and Endovascular Neurosurgery Divisions at Brigham and Women’s Hospital, and was formerly an interventional neuroradiologist at the Massachusetts General Hospital. From 1994 through 1998, prior to his appointment at Massachusetts General Hospital, Dr. Norbash is a career interventional and diagnostic neuroradiologist, and was previously director of Head and Neck Imaging, and director of Neuro-Magnetic Resonance Therapy at Stanford University Hospital.
Dr. Norbash’s research interests have focused on neurointerventional tool development for the treatment of vascular disorders of the brain and spinal cord, with a concentration on aneurysms, stroke and the treatment of atherosclerotic disorders. Dr. Norbash has given over 340 national and international lectures, and also published over 140 original and review articles and abstracts. He is a member of many professional organizations, including Alpha Omega Alpha, the Radiological Society of North America and the American Stroke Association. He has also developed clinical products that are currently being utilized in the treatment of vascular disorders of the head, neck and spine. He has mentored numerous trainees in radiology including many now active in academic careers.
Dr. Pande is an Assistant Professor of Medicine at Boston University School of Medicine and Director of Endovascular and Structural Heart Interventions as a staff member of the Cardiovascular Medicine section at Boston Medical Center. A graduate of Harvard College and Duke University School of Medicine, Dr. Pande has completed advanced training in cardiology at Brigham and Women’s Hospital in Boston, where he performed his residency. This training has included post-doctoral fellowships in cardiovascular medicine and interventional cardiology, as well as an advanced fellowship in peripheral vascular disease and structural interventions. He also was chief resident in medicine at the Veterans Affairs Medical Center in West Roxbury. He is board certified in internal medicine, cardiovascular disease, interventional cardiology, and endovascular medicine. He is a member of the American College of Cardiology and a Fellow of the Society for Cardiovascular Angiography and Interventions.
In addition, Dr. Pande was a post-doctoral research fellow studying atherosclerosis at the Center for Molecular Imaging Research at Massachusetts General Hospital, Boston. His research has been published in peer-reviewed journals, and he has contributed to several textbook chapters on heart disease. His areas of clinical interest include complex coronary artery angioplasty and stenting, medical and interventional management of peripheral vascular disease, structural heart disease including closure of patent foramen ovale and atrial septal defects, and minimally-invasive treatments for valvular heart disease. Dr. Pande joined the Cardiovascular Medicine Section and Cardiac Catheterization Laboratory at Boston Medicine Center in August 2009 from St. Elizabeth’s Medical Center and Tufts University School of Medicine, where he was Director of Structural Heart Disease and an Assistant Professor of Medicine. Dr. Pande is currently serving as the primary investigator at BMC for industry-sponsored clinical trials involving carotid stenting.
Tania J. Phillips, MD
Dr. Phillips completed her medical training and an intercalated B.Sc., Honours Program in Physiology and Immunology, at Guys Hospital Medical School, University of London in 1979. After internships in internal medicine and general and vascular surgery, she gained postgraduate experience in general medicine, cardiology, intensive care and thoracic medicine at the Whittington, Brompton and Royal London Hospitals. After becoming a member of the Royal College of Physicians, Dr. Phillips trained in Dermatology at the London Hospital and also had an appointment at St. John’s Hospital for Diseases of the Skin. In 1986 she did a Dermatology Fellowship at Boston University School of Medicine and Harvard Medical School, and subsequently joined the faculty at Boston University School of Medicine. She is Director of the Wound Healing Clinic and Director of the Dermatology Clinical Research Center at Boston Medical Center. Her clinical experience in wound healing includes the evaluation and treatment of cutaneous manifestations of chronic venous disease. Her clinical leadership in wound and venous skin care provide a valuable resource for potential research into venous disease for the Vascular Medicine Fellows. Her research interest is wound healing, particularly in the use of cultured skin and skin substitutes. She has won numerous awards and prizes including the Venous Research Award of the American Venous Forum and the Young Investigator Award of the American Society for Dermatologic Surgery. She has lectured as numerous national and international meetings and is on the editorial board of Wounds and the Journal of Dermatologic Surgery. She is a panel member of the FDA General and Plastic Surgery Devices Advisory Committee. She is also a member of the Medical Research Planning Committee as well as the Symposium of Advanced Wound Care Planning Committee. She is a member of the Board of Directors of the Women’s Dermatologic Society and the Association for the Advancement of Wound Care. She has co-authored three books and over 100 scientific publications. She has also assumed an active role in the education and mentoring of many students, residents and fellows (including vascular surgery fellows) in both clinical dermatology and research into wound care. The clinical and research activities of Dr Phillips would provide our fellows with a valuable resource to learn about wound care and potentially develop research project in venous disease and wound healing.
Rick Ruberg, MD
Dr. Ruberg is an Assistant Professor of Medicine and Radiology at Boston University School of Medicine and the Co-Director of the Advanced Cardiac Imaging Program at Boston Medical Center. Dr. Ruberg is also the Co-Director of the Cardiovascular Fellowship Training Program. He is board certified in internal medicine, cardiovascular disease, and adult comprehensive echocardiography. Dr. Ruberg is a graduate of the University of Pennsylvania School of Medicine in Philadelphia, PA, and completed his internal medicine training at Brigham and Womens’ Hospital, cardiology fellowship at Boston Medical Center, and cardiac magnetic resonance imaging (MRI) fellowship at Beth Israel Deaconess Medical Center, all in Boston. His clinical expertise is in newer cardiac imaging technologies such as echocardiography, cardiac MRI, and cardiac CT. Dr. Ruberg’s clinical interest is in diastolic heart failure, serving as a consulting cardiologist to the BU Amyloid Treatment and Research Program.
Dr. Ruberg’s research interest is in the translational application of MRI-based techniques to quantify lipid (fat) deposition in the vasculature of patients with vascular disease, as well as gain insight into the association between metabolic syndrome and vascular dysfunction. He is a co-investigator on an NIH-funded grant “Vascular Consequences of Insulin Resistance and Obesity,” led by Dr. Joseph Vita. Dr. Ruberg also works in collaboration with investigators from Biophysics and Biomedical Engineering at Boston University to develop novel imaging strategies and targeted reagents to identify inflammation and lipid deposition in vascular disease.
Joseph Vita, MD
Dr. Vita is a Professor of Medicine at Boston University School of Medicine and a senior staff cardiologist in the Section of Cardiovascular Medicine. He is a member of the American Society for Clinical Investigation and the Association of University Cardiologists. He is a Fellow of the American College of Cardiology, and the American Heart Association Councils on Arteriosclerosis, Thrombosis, Basic Cardiovascular Sciences and Clinical Cardiology. Dr. Vita is a member of Cardiovascular Diseases Board of the American Board of Internal Medicine. He has served on numerous study sections for the NIH and American Heart Association and is a former Chair of the Cardiovascular Pathophysiology Study Section for the AHA. Dr. Vita is a member of the editorial boards of the American Journal of Physiology, Journal of the American College of Cardiology, and Coronary Artery Disease, and currently serves as Deputy Editor of the journal Circulation.
Dr. Vita’s current clinical activities include consultative cardiology and attending in the coronary care unit. Dr. Vita supervises a translational research program in vascular biology with a focus on mechanisms and clinical consequences of endothelial dysfunction. Dr. Vita successfully competed for RFA-HL-03-003 “Clinical Research in Peripheral Arterial Disease”, which currently funds an RO1 grant entitled “Clinical Utility of Endothelial Function in PAD”. He also is the Principal investigator of a SCCOR Grant on Vascular Injury, Remodeling, and Repair entitled Vascular Consequences of Insulin Resistance and Obesity.
Dr. Vita has a strong track record for mentoring research fellows and a number of his former fellows hold faculty positions and have national grant support. Dr. Vita is a co-investigator on the Boston University Clinical Research Training Program (CREST), a K30 training program led by Dr. David Felson. As part of this training grant, he serves as the mentor for CREST fellows, lectures on translational research, and critically reviews fellow research presentations.
Philip A. Wolf, MD
Dr. Wolf has been an active investigator in epidemiological studies of neurological diseases, principally stroke. He has been affiliated with The Framingham Heart Study for more than 35 years and is currently Principal Investigator of the National Heart, Lung and Blood Institute Contract to conduct examinations and maintain surveillance of the Framingham Study cohorts. He is principal investigator of the MRI, Genetics and Cognitive Precursors of AD and Dementia Project, Epidemiology of Dementia Study, and the Precursors of Stroke Incidence and Prognosis Study, all NIH-funded research programs. He was selected by the Institute of Neurologic Diseases and Stroke to receive a Jacob A. Javits Neuroscience Award. He was the first to receive the Humana Award for Excellence in Clinical Stroke of the Stroke Council of the American Heart Association. He is the recipient of the American Stroke Association’s C. Miller Fisher Award in 2000. Dr. Wolf is a member or fellow of numerous professional associations, including the American Neurologic Association and the American Epidemiologic Society. He is a fellow of the AHA’s Stroke and Epidemiology Councils and served on the Executive Committee of both Councils as well as the editorial board of the journal Stroke. He is author of more than 200 peer-reviewed papers and one of five Editors of the 4th Edition of the textbook Stroke – Pathophysiology, Diagnosis, and Management (2004).
For many years he was Chief of the Cerebrovascular Disease Section of the Department of Neurology and directed a number of international cooperative clinical studies of stroke: The NINDS Stroke Data Bank, The Ticlopidine-Aspirin Stroke Study (TASS), Boston Area Anticoagulation Trial in Atrial Fibrillation (BAATAF), North American Symptomatic Carotid Endarterectomy Trial (NASCET) and the Clopidogrel-Aspirin Prevention of Ischemic Events Study (CAPRIE). He has also served on Executive Committees and Data Safety Monitoring Boards for a number of NIH and industry supported studies of Stroke: TASS, BAATAF, NASCET, BRAVO, VISP, TRENDS, WHI Stroke Study, and ProFESS. He serves on the Monitoring Boards of two NHLBI studies the Cardiovascular Health Study and The Jackson Heart Study. During his career at the Framingham Heart Study Dr. Wolf has mentored many clinical investigators in conducting epidemiologic research with numerous trainees pursuing long-term academic careers. With expertise in investigating stroke prevention and carotid artery disease, Dr. Wolf remains eager to participate in the development our vascular medicine fellows.